Skip to main content

It looks like you are visiting from outside the EU. Switch to the US version to see local pricing in USD and local shipping.

Switch to US ($)
Contact +33 (0)3 90 20 54 70
📢 -40% on Recombinant Antibody Production. Available until January 31, 2026 on your first order. Code: RECAB40
cancer cells

Patient-Derived Cancer Antibody Library for Phage Display

Obtain tumor-specific fully human antibodies derived from cancer donors in just 4 weeks.

Contact us Talk to our experts
0x10¹⁰
huge diversity of antibodies
0st
world’s immune cancer library
0
cancers covered
0
guaranteed therapeutic binders

Reduce time and development costs with the fastest path to cancer-specific antibodies

  • Built from a dual source, our library captures up to 90% of the human antibody-producing B cells. This ensures access to clinically relevant targets, including self-antigens, neoantigens, and MHC–peptide complexes, and many targets that synthetic libraries fail to reach.

Let’s discuss your antibody needs

 

Access rare self-targeting antibodies with the broadest cancer library in the world

The LiAb-SFCANCER™ is built from 86 cancer patients across 18 indications, providing an exceptionally diverse repertoire: 6.81×10¹⁰ scFv and 6.72×10¹⁰ Fab clones.

Our phage display library includes rare malignancies—B-lymphoblastic leukemia (B-ALL), B-lymphoblastic lymphoma (B-LL), and multiple myeloma— characterized by a high proliferation of pre-B cells that recognize self-antigens, making LiAb-SFCANCER™ a unique library worldwide.  

 

Tell us about your cancer project!

Secure your success with 3 guaranteed leads and zero royalties

3 guaranteed therapeutic binders

We deliver a minimum of three validated binders, giving you backup candidates to secure your success.

4 weeks from antigen design to antibody sequence

Save valuable time with a streamlined sequence-to-antibody workflow without compromising quality or performance.

Retain full intellectual property rights

Without royalties or licensing fees, you maintain full control over your downstream development. 

Your cancer-specific antibodies in just 4 weeks

 

From antigen production to antibody sequence

Antigen procurement or design and production
  • You deliver the antigen to us
  • Or, we make the antigen for you
Immune Library Screening and Biopanning
  • Screening of our pre-built immune library for antigen binders
  • 4-6 rounds of biopanning
Screening & binder validation by ELISA
  • Identification of 3-10 functional binders
DNA Extraction & Antibody Sequencing
  • Delivery of your antibody sequences
Each project is overseen by a dedicated PhD-level project manager who will guide you at every step. 

 
Get personalized guidance

Your go-to phage display library for the toughest oncology applications

See how this unique phage display library accelerates progress across multiple oncology use cases. By providing human cancer-specific antibodies with low engineering requirements and reduced immunogenicity risks, you accelerate the development of your antibody against challenging targets and its transition to the preclinical stage. 

 

Antibodies in pink background

Discover antibodies against rare or patient-specific tumor antigens

  • Identify antibodies against neoantigens unique to a patient’s tumor for personalized therapy.
  • Target rare tumor-specific antigens in pancreatic or ovarian cancer, often missed by conventional libraries.

Target challenging antigens

  • Develop antibodies against intracellular tumor antigens presented on MHC, highly conserved antigens, or self-antigens.
  • Access complex targets like certain immune checkpoints (TIM-3, LAG-3).

Screen multiple indications in parallel

  • Run multi-target campaigns without having to build separate libraries for each tumor type.
  • Quickly identify hits that could be relevant for multiple indications, increasing the flexibility of your pipeline. 

Discover companion diagnostics and biomarker discovery

  • Identify tumor-associated autoantibodies as early detection biomarkers.
  • Develop IHC, flow cytometry, or ELISA reagents for patient stratification or biomarker validation. 

3 therapeutic antibodies in the market. 30+ in preclinical and clinical development. Let’s create yours!

 

  • Case report
    TCR-Like Antibody Development For Cancer Immunotherapy

    Explore how we designed an antibody against a target barely visible to the immune system. 

    Read the full article

  • Webinar
    Overcoming Challenges of Neutralizing Antibodies in Cancer Therapy using Innovative Phage Display Technologies

    Explore how innovative phage display technologies, powered by our antibody library derived from cancer patients, can accelerate the development of novel therapeutics while saving time and reducing animal use.

    Watch the webinar

  • Scientific Publication 
    Construction of a Human Immune Library from Gallbladder Cancer Patients for the Single-Chain Fragment Variable (scFv) Antibody Selection against Claudin 18.2 via Phage Display

    Discover the relevance of our LiAb-SFCANCERTM Library for developing antibodies against cancer antigens. 

    Go to the scientific article

 

FAQs about our cancer immune library 
Related Services
Therapeutic Antibody Discovery Services Phage Display Services Custom Antibody Production Human Autoimmune Antibody Library

Need a quote or more information? Contact us!

    Cart (0 Items)

    Your cart is currently empty.

    View Products